Aclaris Therapeutics, Inc. (ACRS) Form 8-K — Aug 6, 2026
Aclaris Therapeutics entered into a Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald on August 6, 2026, re-establishing its at-the-market equity offering program under a Form S-3 registration statement. Under the agreement, Aclaris may sell common stock from time to time at its sole discretion through the two agents, paying a 3.0% commission on gross sales proceeds; the company is not obligated to make any sales. The new agreement amends and restates a February 27, 2025 sales agreement that had provided for up to $100.0 million of sales, and the filing does not state a new dollar cap beyond what is registered.
Key figures
- Selling Commission
- 3.0% of gross sales proceeds
- Termination Notice
- 10 trading days by either party
- Agent Counsel Fee Caps
- $75,000 at execution; $25,000 per 10-K Triggering Event; $15,000 per 10-Q Triggering Event
- Prior Atm Program Capacity
- $100.0 million (prior agreement dated February 27, 2025, which this agreement amends and restates)
Price after filing
Close on the filing date to close N calendar days later (from $5.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.